Organization Profile

You just read:

Hepatitis C cure rate of 97 per cent announced in study of patients co-infected with HIV given 12-week combination treatment of daclatasvir and sofosbuvir in ALLY-2 trial

News provided by

Bristol-Myers Squibb Canada

Mar 03, 2015, 05:59 ET